UBS AM’s Adicet Bio ACET Stock Holding History

UBS AM’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,017	Closed	-$186K	–	2588
2023 Q2	$186K	Hold	2,017	–	–	﹤0.01%	2577
2023 Q1	$186K	Buy	+2,017	New	+$253K	﹤0.01%	2577
2022 Q3	–	Sell	-656	Closed	-$153K	–	2739
2022 Q2	$153K	Buy	+656	New	+$144K	﹤0.01%	2610

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

UBS AM's ACET Position: Q3 2023 in Review

UBS AM sold out of Adicet Bio (ACET) in Q3 2023, closing a stake of 2,017 shares — an estimated $186K sold.

UBS AM first reported a position in ACET in Q2 2022 and held it in 3 quarters. The position peaked at $186K in Q2 2023. 83 funds tracked by Wall St. Rank hold ACET as of Q3 2023.

UBS AM reported no remaining Adicet Bio position as of Q3 2023 after selling out during the quarter.
UBS AM sold 2,017 Adicet Bio shares in Q3 2023, an estimated $186K.
UBS AM first reported a position in Adicet Bio in Q2 2022 and held it in 3 quarters.
UBS AM's Adicet Bio position peaked at $186K in Q2 2023.
83 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.